Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 4/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17053411 | 0.83 | KCNA3 (0.40) | KCNA3CYP3A4TSHRCYP2C19EPHX1 | |
| SCHEMBL17035459 | 0.81 | CHRM1 (0.37) | KCNA3EPHX1 | |
| SCHEMBL17032893 | 0.81 | KCNA3 (0.38) | KCNA3CYP3A4TSHRCYP2C19EPHX1 | |
| SCHEMBL17050226 | 0.79 | KCNA3 (0.37) | KCNA3CYP3A4TSHRCYP2C19EPHX1 | |
| SCHEMBL14501550 | 0.78 | EPHX1 (0.47) | KCNA3CYP3A4TSHRCYP2C19EPHX1 | |
| SCHEMBL17032892 | 0.76 | KCNA3 (0.35) | KCNA3CYP3A4TSHRCYP2C19EPHX1 | |
| SCHEMBL8243916 | 0.76 | EPHX1 (0.55) | KCNA3CYP3A4TSHRCYP2C19EPHX1 | |
| SCHEMBL8395605 | 0.76 | EPHX1 (0.50) | KCNA3CYP3A4TSHRCYP2C19EPHX1 | |
| SCHEMBL11153395 | 0.74 | EPHX1 (0.58) | KCNA3CYP3A4TSHRCYP2C19EPHX1 | |
| SCHEMBL25978959 | 0.72 | EPHX1 (0.42) | KCNA3CYP3A4TSHRCYP2C19EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4129407-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-3110418-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20170226142-A1 | Factor D Inhibitors Useful for Treating Inflammatory Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170226142-A1 | Factor D Inhibitors Useful for Treating Inflammatory Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-9643986-B2 | Factor D inhibitors useful for treating inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643986-B2 | Factor D inhibitors useful for treating inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160362398-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362433-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362399-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| WO-2015130830-A9 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2015130842-A9 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| WO-2015130838-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015130830-A1 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015130842-A2 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015130806-A1 | AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015130845-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015130784-A1 | ALKYNE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015130795-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| US-20150239837-A1 | Factor D Inhibitors Useful for Treating Inflammatory Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362433-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, C9, TFPI | KCNA3 2275/4885CYP3A4 1255/4885TSHR 1898/4885 |
| US-20160362398-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, CFH | KCNA3 2755/4885CYP3A4 3388/4885TSHR 1558/4885 |
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, CFH, TFPI | KCNA3 3495/4885CYP3A4 4376/4885TSHR 3158/4885 |
| US-20150239837-A1 | Factor D Inhibitors Useful for Treating Inflammatory Disorders | CFD, TFPI, TFPI2 | KCNA3 3818/4885CYP3A4 4361/4885TSHR 2791/4885 |
| US-20170226142-A1 | Factor D Inhibitors Useful for Treating Inflammatory Disorders | CFD, TFPI, TFPI2 | KCNA3 3818/4885CYP3A4 4361/4885TSHR 2791/4885 |
| US-20160362399-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, CFH, TFPI | KCNA3 2029/4885CYP3A4 1037/4885TSHR 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.